ENDRA Life Sciences' mission is to bring new capabilities to ultrasound and broaden access to better healthcare.
ENDRA is developing a next generation Thermo-Acoustic Enhanced UltraSound (TAEUS™) system to enable clinicians to visualize human tissue composition, function and temperature in ways previously possible only with CT & MRI -- at a fraction of the cost, and at the point-of-care.
ENDRA's first TAEUS application will focus on the quantification of fat in the liver, for early detection and monitoring of Non-Alcoholic Fatty Liver Disease, which affects over 1 billion people globally.
|Oct 14, 2019||ENDRA Life Sciences to present at H.C. Wainwright 3rd Annual NASH Investor Conference|
|Sep 26, 2019||ENDRA Life Sciences Reports Completion and Top Level Findings of Second Phase of Robarts Research Institute Liver Fat Feasibility Study|
|Sep 10, 2019||ENDRA Life Sciences to Showcase TAEUS(TM) Liver Application at the EASL Non-Alcoholic Fatty Liver Disease Summit in Seville, Spain on September 26-28, 2019|
|Aug 21, 2019||ENDRA Life Sciences to Participate at Upcoming Investor Conferences|
|Aug 08, 2019||ENDRA Life Sciences Reports Second Quarter 2019 Financial & Operational Results|
|Day Range||1.15 - 1.23|
|52 Week Range||0.90 - 5.75|
|Bid/Ask||1.15 / 1.18|
|Bid/Ask Size||1,600 X 100|
|Market Cap||8.78 million|
|Shares Outstanding||7.42 million|
|Dividend/Yield||0.00 / 0.00%|
|P/E Ratio (TTM)||N/A|